Skip to cookie consent Skip to main content

Portfolio Companies

We support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. Since inception in 2008, we have invested in 55 companies, realized 16 successful exits, and produced top venture returns.

Active portfolio companies

  • zoomed in view of cells
    Abcuro

    Abcuro is developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.

  • lab dish with clear liquid on top
    Affinia Therapeutics

    Affinia is developing next-generation AAV gene therapies for rare and non-rare diseases. 

  • abstract graphic of molecules and ribbons
    Amolyt Pharma

    Amolyt is developing therapeutic peptides for rare endocrine and metabolic diseases.

  • abstract image of human eye
    Claris Bio

    Claris is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases. 

  • illustration showing neurodegenerative diseases of the eye
    FireCyte Therapeutics

    FireCyte is developing novel treatment strategies for progressive neurodegenerative diseases of the eye.

  • zoomed in view of molecules
    Garuda Therapeutics

    Garuda is pioneering off-the shelf, long-term hematopoietic stem cell (LT-HSC)-based cellular therapies. 

  • child sitting against a wall with head in his legs
    InStride Health

    Co-founded by clinicians from McLean Hospital, InStride offers technology-enhanced mental health treatment for adolescents.

  • hand holding 2 pills
    Lyndra Therapeutics

    Lyndra is developing orally administered, ultra-long-acting, sustained-release drugs. The pipeline includes therapies for Alzheimer’s disease, HIV, and a once-monthly option for oral contraception.

  • scientific image showing fibrosis treatment
    Mediar Therapeutics

    Mediar is developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

  • abstract image of neurons
    Nocion Therapeutics

    Nocion is developing novel small molecule charged sodium channel blockers, “nocions,” that selectively affect actively firing nociceptors to treat neuroinflammatory indications. 

  • abstract image of neurons and dna
    Paros Bio

    Paros Bio is developing transformative gene therapies for the treatment of Autosomal Dominant Alzheimer’s Disease.

  • abstract image of molecules
    Photys

    Photys is developing a new class of bifunctional drugs for phosphorylation of kinases to treat cancer.

  • image of the retina
    Pykus

    Pykus is developing a novel intraocular polymer to replace the vitreous humor following retinal surgery. 

  • pills, needle and drug containter on table with ALS in text
    QurAlis

    QurAlis is developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases. 

  • older woman in hospital gown talking to provider
    Rippl Care

    Rippl is pioneering a new care model to expand access to mental health care for seniors, their families, and caregivers.

  • abstract image of a neuron
    ROME Therapeutics

    Rome is unlocking the hidden genome by targeting the RNA "repeatome" to treat autoimmune disease and cancer.

  • red scorpoin graphic
    Scorpion Therapeutics

    Scorpion is a next-generation precision oncology company.

  • researcher pipetting samples in lab
    SeQure Dx

    SeQure Dx applies best-in-class technology to identify and manage the risks of off-target gene-editing agents.

  • abstract image of dna strand
    SwanBio Therapeutics

    SwanBio is advancing AAV-based gene therapies for the treatment of neurological diseases, including adrenomyeloneuropathy.

  • kidney medical illustration
    Walden BioSciences

    Walden BioSciences is transforming the treatment of kidney disease by restoring or preserving podocyte function. 

  • zoomed in view of cells
    Ziel Bio

    ZielBio is developing targeted therapies against novel targets for cancer. 

Exited portfolio companies

Since inception, Mass General Brigham Ventures has realized 16 exits, including seven initial public offerings and nine trade sales. These portfolio companies are spearheading novel approaches to diagnose, prevent and treat a wide range of medical conditions.

Acquisitions

  • doctor examining hand of a patient

    Adheron Therapeutics


    Acquired by Roche (ADR: RHHBY)
    Oct. 2015
    Monoclonal antibody (mAb) therapy for inflammatory diseases including Rheumatoid Arthritis.

  • woman in operating room about have oxygen mask placed on her

    Annovation BioPharma


    Acquired by The Medicines Company (NASDAQ: MDCO)
    Jan. 2015
    Novel precision anesthetics.

  • abstract image of viruses

    CoStim Pharmaceuticals


    Acquired by Novartis (NYSE: NVS)
    Feb. 2014
    Next-generation immuno-oncology drugs based on T-cell costimulatory targets.

  • clinician holding slide with brain scans

    LifeImage


    Acquired by InteleRad Medical Systems
    Sep. 2022
    Digital diagnostic image sharing platform.

  • one colored dna surrounded by non colored dna

    Lysosomal Therapeutics


    Acquired by Bial Biotech
    Oct. 2020
    Novel personalized medicine platform to treat neurodegenerative diseases, targeting the mutant GBA1 gene.

  • doctor using tablet to view patient information

    QPID Health


    Acquired by eviCore Healthcare
    Feb. 2016
    EHR analytics software – extracting insight from information.

  • close up illustration of 3D cells

    Syntimmune


    Acquired by Alexion (NASDAQ:ALXN)
    Nov. 2018
    Advances the fight against autoimmune disease.

  • illustration of colorful molecules

    Tilos Therapeutics


    Acquired by Merck (NYSE: MRK)
    June 2019
    Anti-LAP antibodies: transforming the tumor microenvironment to treat cancer.

IPOs

  • physician examining child's ear
    Akouos

    IPO June 2020 (NASDAQ: AKUS); acquired by Lilly (NYSE: LLY) Dec. 2022
    Precision genetic medicine company focused on inner ear disorders, including sensorineural hearing loss.

  • illustration showing brain waves
    Denali Therapeutics

    IPO Dec. 2017 (NASDAQ: DNLI)
    Defeating neurodegenerative diseases.

  • colorful dna ribbons intertwined
    Editas Medicine

    IPO Feb. 2016 (NASDAQ: EDIT)
    Unlocking the power and potential of CRISPR genome editing technology.

  • slide showing zoomed in cells dyed red
    Keros Therapeutics

    IPO April 2020 (NASDAQ: KROS)
    Novel treatments for patients suffering from hematologic and musculoskeletal disorders.

  • researcher piping a sample in lab
    Magenta

    IPO June 2018 (NASDAQ: MGTA)
    Revolutionizing stem cell transplant as the new treatment paradigm for immunologic and blood-based diseases.

  • close of cells with bacteria
    Spero Therapeutics

    IPO Nov. 2017 (NASDAQ: SPRO)
    Anti-infectives targeting Gram-negative bacteria.

  • mrna
    Translate Bio

    IPO June 2018 (NASDAQ:TBIO), acquired by Sanofi (NASDAQ: SNY) Sep. 2021
    Developing messenger RNA (mRNA) therapies. 

  • abstact illustration of dna strand
    Verve Therapeutics

    IPO June 2021 (NASDAQ:VERV)
    Pioneering single-course gene editing medicines to treat cardiovascular disease.